MAIA Biotechnology Announces $4 Million Registered Direct Offering
15 Novembro 2023 - 11:35AM
Business Wire
MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA” or the
“Company”), a clinical-stage biopharmaceutical company developing
telomere-targeting immunotherapies for cancer, today announced that
it has entered into a definitive agreement for the issuance and
sale of an aggregate of 2,424,243 of its shares of common stock at
a purchase price of $1.65 per share in a registered direct
offering. In a concurrent private placement, MAIA has also agreed
to issue and sell unregistered warrants to purchase up to an
aggregate of 2,424,243 shares of its common stock. The offering is
expected to close on or about November 17, 2023, subject to the
satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement
agent for the offering.
The unregistered warrants will have an exercise price $1.86 per
share, will become exercisable six months following issuance and
will expire five and one-half years from the date of issuance.
The gross proceeds to MAIA from the offering are expected to be
approximately $4 million, before deducting the placement agent’s
fees and other offering expenses payable by the Company. MAIA
currently intends to use the net proceeds from the offering for
working capital and general corporate purposes as well as to fund
research and development activities.
The shares of common stock offered in the registered direct
offering (but excluding the unregistered warrants offered in the
concurrent private placement and the shares of common stock
underlying such unregistered warrants) are being offered and sold
by the Company pursuant to a “shelf” registration statement on Form
S-3 (Registration No. 333-273984), including a base prospectus,
previously filed with the Securities and Exchange Commission (SEC)
on August 15, 2023 and declared effective by the SEC on August 23,
2023. The offering of the shares of common stock to be issued in
the registered direct offering are being made only by means of a
prospectus supplement that forms a part of the registration
statement. A final prospectus supplement and an accompanying base
prospectus relating to the registered direct offering will be filed
with the SEC and will be available on the SEC’s website located at
http://www.sec.gov. Electronic copies of the final prospectus
supplement and accompanying base prospectus may also be obtained,
when available, by contacting H.C. Wainwright & Co., LLC at 430
Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212)
856-5711 or e-mail at placements@hcwco.com.
The offer and sale of the unregistered warrants in the private
placement are being made in a transaction not involving a public
offering and have not been registered under Section 4(a)(2) of the
Securities Act of 1933, as amended (the “Securities Act”) and/or
Rule 506(b) of Regulation D promulgated thereunder and, along with
the shares of common stock underlying such unregistered warrants,
have not been registered under the Securities Act or applicable
state securities laws. Accordingly, the unregistered warrants
offered in the private placement and the underlying shares of
common stock may not be reoffered or resold in the United States
except pursuant to an effective registration statement or an
applicable exemption from the registration requirements of the
Securities Act and such applicable state securities laws.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or jurisdiction.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on
the development and commercialization of potential first-in-class
drugs with novel mechanisms of action that are intended to
meaningfully improve and extend the lives of people with cancer.
Our lead program is THIO, a potential first-in-class cancer
telomere targeting agent in clinical development for the treatment
of NSCLC patients with telomerase-positive cancer cells. For more
information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of
historical facts contained in this press release, are
forward-looking statements. Forward-looking statements are subject
to known and unknown risks, uncertainties, and other factors that
may cause our or our industry’s actual results, levels or activity,
performance or achievements to be materially different from those
anticipated by such statements. The use of words such as “may,”
“might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,”
“believe,” “estimate,” “project,” “intend,” “future,” “potential,”
or “continue,” and other similar expressions are intended to
identify forward looking statements. However, the absence of these
words does not mean that statements are not forward-looking. For
example, all statements we make regarding (i) the initiation,
timing, cost, progress and results of our preclinical and clinical
studies and our research and development programs, (ii) our ability
to advance product candidates into, and successfully complete,
clinical studies, (iii) the timing or likelihood of regulatory
filings and approvals, (iv) our ability to develop, manufacture and
commercialize our product candidates and to improve the
manufacturing process, (v) the rate and degree of market acceptance
of our product candidates, (vi) the size and growth potential of
the markets for our product candidates and our ability to serve
those markets, (vii) our expectations regarding our ability to
obtain and maintain intellectual property protection for our
product candidates, and (viii) the completion of the offering, the
satisfaction of customary closing conditions related to the
offering and the anticipated use of proceeds therefrom, are forward
looking. All forward-looking statements are based on current
estimates, assumptions and expectations by our management that,
although we believe to be reasonable, are inherently uncertain. Any
forward-looking statement expressing an expectation or belief as to
future events is expressed in good faith and believed to be
reasonable at the time such forward-looking statement is made.
However, these statements are not guarantees of future events and
are subject to risks and uncertainties, including market and other
conditions, and other factors beyond our control that may cause
actual results to differ materially from those expressed in any
forward-looking statement. Any forward-looking statement speaks
only as of the date on which it was made. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise, except as required by law. In this release, unless the
context requires otherwise, “MAIA,” “Company,” “we,” “our,” and
“us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231115523423/en/
Investor Relations and Inquiries ir@maiabiotech.com
Maia Biotechnology (AMEX:MAIA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Maia Biotechnology (AMEX:MAIA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024